Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023
January 16, 2024 at 04:16 pm EST
Share
Burzynski Research Institute, Inc. reported earnings results for the third quarter and nine months ended November 30, 2023. For the third quarter, the company reported net loss was USD 0.433015 million compared to USD 0.252639 million a year ago.
For the nine months, net loss was USD 0.972524 million compared to USD 0.700294 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.
BURZYNSKI RESEARCH INSTITUTE, INC. 
